Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Liposomal Bupivacaine Dose Escalation in Healthy Volunteers
NCT05456490Phase 1Completed
- Sponsor
- Pacira BioSciences
- Start
- Apr 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of liposomal bupivacaine in pain (3 arms), sponsored by Pacira BioSciences. Primary endpoints: Area under the plasma concentration-versus-time curve from time 0 to the last measurable concentration, Area under the plasma concentration-versus-time curve from time 0 to infinity and 5 more. Started Apr 2023; status: completed.
02
Drugs
liposomal bupivacaine
03
Conditions
pain
Beyond the preview
Go deeper on NCT05456490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456490.